REC-4881 is under clinical development by Recursion Pharmaceuticals and currently in Phase II for Familial Adenomatous Polyposis. According to GlobalData, Phase II drugs for Familial Adenomatous Polyposis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the REC-4881 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

REC-4881 overview

REC-4881 is under development for the treatment of familial adenomatous polyposis, solid tumor, colorectal cancer, hepatocellular carcinoma and ovarian cancer. The drug candidate is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.

It was under development for the treatment of solid tumors (non-hematologic malignancy) and metastatic melanoma, hereditary cancer syndrome, solid tumors.

Recursion Pharmaceuticals overview

Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. It provides products that include a Robotics Platform, Recursion Operating System. Recursion has the pipeline disease model which includes Phase II Candidate: Cerebral Cavernous Malformation, Phase I Candidate: Neurofibromatosis Type 2, Phase I Candidate: Familial Adenomatous Polyposis, Phase I Candidate: GM2 Gangliosidosis. The company also offers target discovery and lead optimization services to its partner companies for furthering their clinical investigation. Recursion is headquartered in Salt Lake City, Utah, the US.

For a complete picture of REC-4881’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.